Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17242605 | 0.86 | KDM4E (0.59) | KDM4EKMT2AMEN1ELANE | |
| SCHEMBL17242582 | 0.84 | KDM4E (0.43) | KDM4EKMT2AMEN1ELANETRAP1 | |
| SCHEMBL17242758 | 0.80 | DDR1 (0.46) | DDR1KDM4ETYMSKMT2ACHRM5 | |
| SCHEMBL17242609 | 0.76 | DDR1 (0.56) | DDR1KDM4EKMT2A | |
| SCHEMBL17242493 | 0.76 | KDM4E (0.58) | KDM4EKMT2AMEN1ELANETRAP1 | |
| SCHEMBL17242545 | 0.74 | KDM4E (0.59) | KDM4EKMT2AMEN1ELANE | |
| SCHEMBL17242573 | 0.74 | TRAP1 (0.48) | DDR1KDM4EKMT2AMEN1TRAP1 | |
| SCHEMBL17241668 | 0.73 | HCRTR1 (0.43) | TYMSHCRTR1HCRTR2 | |
| SCHEMBL17242581 | 0.71 | TRAP1 (0.46) | DDR1KDM4EKMT2AMEN1TRAP1 | |
| SCHEMBL4595781 | 0.69 | LMNA (0.64) | KDM4ETYMSHCRTR1HCRTR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2017-05-18 | — | — | US | disclosed |
| EP-3140301-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | Orion Corporation (FI) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015169999-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | GABRB1, GABRB3, GABRB2 | DDR1 1919/4885KDM4E 1998/4885TYMS 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.